HSIC
60
-2
FCX
57
-2
LLY
53
6
HBI
59
4
MSFT
57
6
PYPL
56
-4
KHC
20
2
EMC
56
-3
MSI
73
3
SO
62
3
SRE
45
-9
O
24
2
COP
47
2
DUK
64
7
UAL
83
-2
PSX
50
3
TSN
42
3
LEN
57
-4
MMM
42
5
PHM
65
-5
HSIC
60
-2
FCX
57
-2
LLY
53
6
HBI
59
4
MSFT
57
6
PYPL
56
-4
KHC
20
2
EMC
56
-3
MSI
73
3
SO
62
3
SRE
45
-9
O
24
2
COP
47
2
DUK
64
7
UAL
83
-2
PSX
50
3
TSN
42
3
LEN
57
-4
MMM
42
5
PHM
65
-5
Financhill
Back

Matinas BioPharma Holdings 10K Form

Sell
38

MTNB
Matinas BioPharma Holdings

Last Price:
0.60
Seasonality Move:
10.6%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MTNB News And Ratings

See the #1 stock for the next 7 days that we like better than MTNB

MTNB Financial Statistics

Sales & Book Value

Annual Sales: $1.1M
Cash Flow: $-3.5M
Price / Cash Flow: 0
Annual Sales: $3.10
Price / Book: 0.2

Profitability

EPS (TTM): -4.79000
Net Income (TTM): $-21.13M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Matinas BioPharma Holdings Earnings Forecast

Key Matinas BioPharma Holdings Financial Ratios

  • The Research & Development expenses have been 1,321.99% of Revenue.
  • The Net Earning history of MTNB is -2,093.25% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Matinas BioPharma Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: MTNB
Website: matinasbiopharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MTNB Technical Analysis vs Fundamental Analysis

Sell
38
Matinas BioPharma Holdings (MTNB) is a Sell

Is Matinas BioPharma Holdings a Buy or a Sell?